PRODIGY, developed by Medtronic for OIRD yields preliminary results

The study was aimed at developing and internally validating the PRODIGY score, which is an accurate OIRD risk assessment scoring tool. Medtronic plc, one of the largest medical technology, services and solutions companies in the world has recently announced that PRODIGY, a study to monitor people at risk of opioid-induced …

Cancer diagnostics firm Burning Rock closes $125.5m Series C funding

The company wants to establish a global leader in tumor precision medicine brand and also lead China’s cancer genetic testing industry. Chinese biotech company Burning Rock has reportedly completed a $125.5 million (850 million yuan) Series C funding round which was led by GIC, the sovereign wealth fund of Singapore. …

Innovent Biologics initiates Phase I clinical trial of IBI101

The clinical study is meant to evaluate the primary efficacy, tolerance and safety of IBI101. Innovent Biologics, Inc., a China based, global biopharmaceutical company that specializes in development, manufacturing and commercialization of superior quality innovative medicines for cancer, immunotherapy and other diseases, recently announced that it will be initiating its …

Cartherics & panCELLa collaborate to develop safe cell therapy

panCELLa welcomed Cartherics as a capable partner in the addressing of needs of cancer patients treated with immunotherapy. Cartherics Pty Ltd, the pluripotent stem cell technology developing Australian company and the Canada based panCELLa Inc, an early-stage biotechnology company, recently announced that they will be collaborating on the research and …

Split-dosing of DARZALEX initial infusion approved by U.S. FDA

The safety profile of DARZALEX was unchanged in case of a split or single initial dose and there were no safety events in case of the split-dosage regimen. The Janssen Pharmaceutica recently announced that it has received approval from the U.S. Food and Drug Administration for split-dosage regimen of DARZALEX®(daratumumab). …

WuXi – Amicus sign exclusive commercial manufacturing partnership

The deal is to be renewed every two years after its initial five-year term and will continue thus until cancelled. WuXi Biologics, a leader in biologics discovery, development and manufacturing offering open-access biologics technology recently announced that it has entered into an exclusive manufacturing partnership with Amicus Therapeutics, a biotechnology …

Kuros Biosciences inks new bone graft supply agreement with SeaSpine

The agreement showcases the interest of prominent orthobiologic firms in Kuros technologies. The global partner would be responsible for marketing an advanced bone graft that would be supplied by Kuros. Kuros Biosciences (Kuros), a renowned Swiss biotechnology company, has reportedly announced that the company’s Dutch subsidiary has entered into an Original …

Precision For Medicine buys ApoCell to expand biomarker capabilities

Precision for Medicine has announced the acquisition of ApoCell, a Houston-based next-generation lab that specializes in the identification and analysis of biomarkers. By acquiring ApoCell, its ApoStream® liquid biopsy technology and extensive tissue profiling expertise will be added to Precision’s strong portfolio of specialty laboratory and biomarker informatics services. The …

Roche invests an upfront of $125M to expand SQZ cell therapy program

SQZ Biotechnologies, a cell therapy conglomerate renowned for developing novel treatments for a wide range of diseases, has recently announced the expansion of its collaboration with Roche in cellular therapy. As per trusted sources, the expanded partnership with Roche’s cancer immunotherapy expertise would further SQZ’s innovation synergistic combination as well …

Roche unveils NGS AVENIO Tumor Tissue Analysis Kits for research use

The Basel headquartered healthcare company Roche Holding AG has globally launched three next-generation sequencing AVENIO Tumor Tissue Analysis Kits for use in oncology research. The new AVENIO Tumor Tissue Targeted Kit, Surveillance Kit and Expanded Kit help to detect all four mutation classes in solid tumors and compliment Roche’s NGS …